



Docket No.: 1296-016

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT OPERATIONS

In re Application of:

Navin Vaya et al

Serial No.: 10/630,348

Filed: July 29, 2003

For: **NOVEL DRUG DELIVERY SYSTEM**

)

) Group Art Unit: 1615

)

)

New York, NY 10036

December 5, 2006

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed under the provisions of
37 CFR§1.97.

U.S. 2004/022849
(Published January 17, 2002
as WO 200203964)

U.S. 5,098,725
(Published February 6, 1991
as EP0411326)

BROPHY et al, "Influence of Coating
and Core Modifications on the In-vitro
Release of Methylene Blue from
Ethylcellulose Microcapsules Produced
by Pan Coating Procedure"; J. Pharm
Pharmacol; 1981; pgs 495-499, No. 33.

Discloses influences of coating and core
modification on release of methylene
blue from pan coated ethylcellulose
microcapsules.


Page Two
December 5, 2006
Docket No: 1296-016

PERUMAL et al, "Effect of Formulation Variables on In-vitro Drug Release and Micromeritic Properties of Modified Release Ibuprofen Microspheres"; 1999; pgs. 4, 475-487; No.16

Disclose effect of formulation variables on in-vitro release and micrometric properties of ibuprofen microcapsules.

Authorization is given to charge the required fee for the filing of this Information Disclosure Statement under 37 CFR§1.97 (c) (2)

Respectfully submitted,



James V. Costigan
Registration No. 25,669

MAILING ADDRESS
HEDMAN & COSTIGAN, P.C.
1185 Avenue of the Americas
New York, NY 10036-2646
(212) 302-8989

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on : December 5, 2006


James V. Costigan, Registration No. 25,669



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2**Complete if Known**

Application Number	10/630,348
Filing Date	July 29, 2003
First Named Inventor	Navin Vaya
Art Unit	--1615
Examiner Name	--Mercier, Melissa S.
Attorney Docket Number	1296-016

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US- 5,098,725	03-24-1992	Rotman et al	
	AB	US- 2004/022849	02-05-2004	Castan et al	
	AC	US-			
	AD	US-			
	AE	US-			
	AF	US-			
	AG	US-			
	AH	US-			
	AI	US-			
	AJ	US-			
	AK	US-			
	AL	US-			
	AM	US-			
	AN	US-			
	AO	US-			
	AP	US-			
	AQ	US-			
	AR	US-			
	AS	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	AT					
	AU					
	AV					
	AW					
	AX					
	AY					

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/630,348
Filing Date	July 29, 2003
First Named Inventor	Navin Vaya, et al.
Art Unit	--1615
Examiner Name	-- Mercier, Melissa S.
Attorney Docket Number	1296-016

Sheet 2 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A	BROPHY et al, "Influence of Coating and Core Modifications on the In-vitro Release of Methylene Blue from Ethylcellulose Microcapsules Produced by Pan Coating Procedure"; J. Pharm Pharmacol; 1981; pgs 495-499, No. 33.	
	B	Perumal et al, "Effect of Formulation Variables on In-vitro Drug Release and Micromeritic Properties of Modified Release Ibuprofen Microspheres"; 1999; pgs. 4, 475-487; No.16	
	C		
	D		
	E		
	F		
	G		
	H		
	I		
	L		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.